Prediction of drug sensitivity and drug resistance in cancer by transcriptional and proteomic profiling - PubMed (original) (raw)
Review
Prediction of drug sensitivity and drug resistance in cancer by transcriptional and proteomic profiling
Moulay A Alaoui-Jamali et al. Drug Resist Updat. 2004 Aug-Oct.
Abstract
The oncologist's challenges, particularly with advanced cancers, are (a) how to predict tumor response to a given drug or regimen; (b) how to predict which tumors of identical histology will remain indolent and which will be likely to progress; and (c) how to determine the appropriate timing of the emergence of drug-resistant cancer cells and hence switch to appropriate therapy. These issues are still unresolved; current clinical practice is hampered by the complexity and heterogeneity of anti-tumor drug resistance where multiple cellular, tumor microenvironment and host factors operate simultaneously. The rapid accumulation of genomic and proteomic databases for complex biological systems, such as cancer, together with advances in technology platforms, have paved the way to an increased molecular understanding and prediction of antitumor drug response. The complex phenotype of drug resistance can now be dissected and specific, clinically relevant markers pinpointed. Several microarray studies of genetic patterns from untreated and pre-treated cancers have provided "fingerprints" that can predict response to therapeutics. Nevertheless, such approaches require further validation in experimental models and in large clinical trials before their routine clinical use. Moreover, comparative transcriptional profiling alone is unlikely to predict drug sensitivity/resistance, a dynamic process where protein phosphorylation, protein trafficking, and protein-protein interactions with secondary effectors play key roles in the fate of cancer cells following therapeutic stress. Functional proteomics is potentially more predictive, but still faces technical challenges with regards to sampling, tumor heterogeneity, and lack of standardized methodologies. These obstacles are surmountable with current concerted research efforts and availability of powerful high-throughput genomic and proteomic instrumentations, and thus approaches to predict and overcome drug resistance could be rationalized.
Similar articles
- Predicting cancer drug response by proteomic profiling.
Ma Y, Ding Z, Qian Y, Shi X, Castranova V, Harner EJ, Guo L. Ma Y, et al. Clin Cancer Res. 2006 Aug 1;12(15):4583-9. doi: 10.1158/1078-0432.CCR-06-0290. Clin Cancer Res. 2006. PMID: 16899605 - New tools for old drugs: Functional genetic screens to optimize current chemotherapy.
Gerhards NM, Rottenberg S. Gerhards NM, et al. Drug Resist Updat. 2018 Jan;36:30-46. doi: 10.1016/j.drup.2018.01.001. Epub 2018 Jan 12. Drug Resist Updat. 2018. PMID: 29499836 Free PMC article. Review. - An integrative genomic and proteomic approach to chemosensitivity prediction.
Ma Y, Ding Z, Qian Y, Wan YW, Tosun K, Shi X, Castranova V, Harner EJ, Guo NL. Ma Y, et al. Int J Oncol. 2009 Jan;34(1):107-15. doi: 10.3892/ijo_00000134. Int J Oncol. 2009. PMID: 19082483 Free PMC article. - The multi-factorial nature of clinical multidrug resistance in cancer.
Assaraf YG, Brozovic A, Gonçalves AC, Jurkovicova D, Linē A, Machuqueiro M, Saponara S, Sarmento-Ribeiro AB, Xavier CPR, Vasconcelos MH. Assaraf YG, et al. Drug Resist Updat. 2019 Sep;46:100645. doi: 10.1016/j.drup.2019.100645. Epub 2019 Sep 17. Drug Resist Updat. 2019. PMID: 31585396 Review. - Proteomics for identifying mechanisms and biomarkers of drug resistance in cancer.
Li XH, Li C, Xiao ZQ. Li XH, et al. J Proteomics. 2011 Nov 18;74(12):2642-9. doi: 10.1016/j.jprot.2011.09.004. Epub 2011 Sep 20. J Proteomics. 2011. PMID: 21964283 Review.
Cited by
- Ocoxin as a complement to first line treatments in cancer.
Benedicto A, Sanz E, Márquez J. Benedicto A, et al. Int J Med Sci. 2021 Jan 1;18(3):835-845. doi: 10.7150/ijms.50122. eCollection 2021. Int J Med Sci. 2021. PMID: 33437220 Free PMC article. Review. - Role of microRNA dysregulation in childhood acute leukemias: Diagnostics, monitoring and therapeutics: A comprehensive review.
Szczepanek J. Szczepanek J. World J Clin Oncol. 2020 Jun 24;11(6):348-369. doi: 10.5306/wjco.v11.i6.348. World J Clin Oncol. 2020. PMID: 32855905 Free PMC article. Review. - BAP18 is involved in upregulation of CCND1/2 transcription to promote cell growth in oral squamous cell carcinoma.
Wang X, Wang C, Yan G, Kang Y, Sun G, Wang S, Zou R, Sun H, Zeng K, Song H, Liu W, Sun N, Liu W, Zhao Y. Wang X, et al. EBioMedicine. 2020 Mar;53:102685. doi: 10.1016/j.ebiom.2020.102685. Epub 2020 Feb 27. EBioMedicine. 2020. PMID: 32113162 Free PMC article. - Recurrent oral cancer: current and emerging therapeutic approaches.
da Silva SD, Hier M, Mlynarek A, Kowalski LP, Alaoui-Jamali MA. da Silva SD, et al. Front Pharmacol. 2012 Jul 30;3:149. doi: 10.3389/fphar.2012.00149. eCollection 2012. Front Pharmacol. 2012. PMID: 23060791 Free PMC article. - Altered phospholipid transfer protein gene expression and serum lipid profile by topotecan.
Saunders RA, Fujii K, Alabanza L, Ravatn R, Kita T, Kudoh K, Oka M, Chin KV. Saunders RA, et al. Biochem Pharmacol. 2010 Aug 1;80(3):362-9. doi: 10.1016/j.bcp.2010.04.015. Epub 2010 Apr 21. Biochem Pharmacol. 2010. PMID: 20416282 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources